Who are NRx Pharmaceuticals, Inc.'s main suppliers?

NRx Pharmaceuticals, Inc. (NRXP) key suppliers include: BTIG-LLC, ALCAMI, NEPHRON-PHARMACEUTICALS, POLYPEPTIDE-GROUP, Johnson & Johnson and 3 more. View the full supplier network at chainsifter.com/chain/NRXP.

Who are NRx Pharmaceuticals, Inc.'s major customers?

NRx Pharmaceuticals, Inc. (NRXP) key customers include: COMMERCIAL-INSURERS, INDIVIDUAL-PATIENTS-AND-CLIENTS, MEDICAID-AND-RELATED-PROGRAMS, NEPHRON-PHARMACEUTICALS, Johnson & Johnson and 3 more. View the full customer network at chainsifter.com/chain/NRXP.

What sector is NRx Pharmaceuticals, Inc. in?

NRx Pharmaceuticals, Inc. (NRXP) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

NRXP Supply Chain: NRx Pharmaceuticals, Inc. Supplier List & 19 Relationships

8Suppliers

8Customers

3Debt Items

20Related Chains

NRx Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
BTIG-LLC	BTIG-LLC	92%	Underwriting Agreement On June 3, 2026, NRx Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with BTIG, LLC, as representative of the se…
ALCAMI	ALCAMI	90%	In December 2022, as part of our agreement with Relief Therapeutics we transferred all manufacturing rights and know-how that we acquired for ZYESAMI (aviptadil) to Relief, including our collaboratio…
NEPHRON-PHARMACEUTICALS	NEPHRON-PHARMACEUTICALS	90%	In December 2022, as part of our agreement with Relief Therapeutics we transferred all manufacturing rights and know-how that we acquired for ZYESAMI (aviptadil) to Relief, including our collaboratio…
POLYPEPTIDE-GROUP	POLYPEPTIDE-GROUP	90%	In December 2022, as part of our agreement with Relief Therapeutics we transferred all manufacturing rights and know-how that we acquired for ZYESAMI (aviptadil) to Relief, including our collaboratio…
JNJ	Johnson & Johnson	72%	alty pharmaceutical and biotechnology companies as well as academic and research institutions. We compete in an industry that is characterized by: (i) rapid technological change, (ii) evolving indust…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from JNJ grap…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from NRXP graph: icinal use, and may not be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, …
ORANY	ORANY	72%	icinal use, and may not be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abus…

NRx Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
COMMERCIAL-INSURERS	COMMERCIAL-INSURERS	90%	The Company receives payments from the following sources: (i) commercial insurers
INDIVIDUAL-PATIENTS-AND-CLIENTS	INDIVIDUAL-PATIENTS-AND-CLIENTS	90%	(iv) individual patients and clients
MEDICAID-AND-RELATED-PROGRAMS	MEDICAID-AND-RELATED-PROGRAMS	90%	(iii) state governments under Medicaid and related programs
NEPHRON-PHARMACEUTICALS	NEPHRON-PHARMACEUTICALS	90%	In 2023, the Company entered into a development and manufacturing agreement with Nephron Pharmaceuticals, Inc. for the manufacture of ketamine HCl (NRX-100, HTX-100) that the Company intends to distr…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from JNJ grap…
JNJ	Johnson & Johnson	72%	alty pharmaceutical and biotechnology companies as well as academic and research institutions. We compete in an industry that is characterized by: (i) rapid technological change, (ii) evolving indust…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	Part D plans include both standalone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not s…

NRx Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
NRXP-DEBT	Debt stack $934,000	90%	Market cache reports total debt of $934,000.
NRXP-DEBT-11371	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
NRXP-DEBT-11370	Warrants outstanding: 270000	90%	xbrl warrant detail from xbrl 2025-12-31.

NRx Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for NRx Pharmaceuticals, Inc..

NRx Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
NRXP-OWNER-B-GROUP-INC	B Group, Inc.	90%	13F overlay lists B Group, Inc. as top holder; 35 tracked holders.

NRx Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CLGN	CollPlant Biotechnologies Ltd.	100.00	2
AURA	Aura Biosciences, Inc.	100.00	2
SNNUF	Smith & Nephew plc	100.00	2
ATRA	Atara Biotherapeutics, Inc.	100.00	2
ADGM	Adagio Medical Holdings, Inc.	100.00	2
ACIU	AC Immune SA	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
CSTE	Caesarstone Ltd.	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
ANIK	Anika Therapeutics, Inc.	100.00	2
BCAX	Bicara Therapeutics Inc.	100.00	2
TRIB	Trinity Biotech plc	100.00	2
ABBV	AbbVie Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
ALC	Alcon Inc.	100.00	2
ATON	AlphaTON Capital Corp	100.00	2

NRx Pharmaceuticals, Inc. Supply Chain